Global STD Testing Market Research Insights, Industry Size 2020 With Alere Inc., Aposcience AG, BCR Biotech Inc., Becton Dickinson And Company - Bandera County Courier
Global STD Testing Market Research Insights, Industry Size 2020 With Alere Inc., Aposcience AG, BCR Biotech Inc., Becton Dickinson And Company - Bandera County Courier |
| Posted: 30 Mar 2020 10:04 AM PDT Global STD Testing Market Report offers an inclusive and decision-making overview, including definitions, classifications and its applications. Global STD Testing Market is anticipated to reflect a positive growth trend in forthcoming years. The essential driving forces behind the growth and popularity Global STD Testing Market is analyzed detailed in this report. Global STD Testing Market By Type (Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing, Chancroid Testing), Location Of Testing (Laboratory Testing, Point Of Care (POC) Testing), Testing Device (Laboratory Devices, Point Of Care (POC) Devices) Geography (North America, South America, Europe, Asia-Pacific, Middle East And Africa) – Industry Trends and Forecast to 2025 The Global STD Testing Market is expected to reach USD 42.73 billion by 2025, from USD 21.86 billion in 2017 growing at a CAGR of 8.6% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Get Exclusive FREE Sample Copy @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-std-testing-market Major Market Competitors/Players: Global STD Testing Market Some of the major players operating in the global STD testing market are Abbott Laboratories, Affymetrix, Inc., Alere Inc., Aposcience AG, BCR Biotech Inc., Becton Dickinson And Company, Biocartis SA, Biomerieux, Bio-Rad Laboratories Inc., Cepheid Inc., Danaher Corporation, DiaSorin, Exogen Biotechnology, Inc., GenMark Diagnostics, Hologic, Inc., OraSure Technologies, Qualigen Inc., Quidel Corporation, Roche Diagnostics, Thermo Fisher Scientific Inc. among others. Market Definition: A group of sicknesses that can be transmitted starting with one individual then onto the next through the sharing of body liquids, vaginal liquids, blood etc is known as STD (Sexually Transmitted Diseases). Sexually transmitted disease incorporates more than 25-30 irresistible illnesses that are spread through sexual exercises. In absence of treatment or mindfulness these infections can prompt significant medical issues, for example, not having the capacity to get pregnant (fruitlessness), lasting cerebrum harm, coronary illness, growth, and even passing as STD has no early indications. A man presented to STD must experience a finding for sexually transmitted maladies in a doctor's facility or a wellbeing center. Regular sexual transmitted illnesses incorporate human immunodeficiency infection, chlamydia, gonorrhea, syphilis, herpes simplex infection, human papilloma infection etc. According to the World Health Organization (WHO), more than 1 million STD are acquired every day globally and there are estimated 357.0 million new infections with STDs chlamydia, gonorrhoea, syphilis and trichomoniasis. Furthermore, more than 500.0 million people to have genital infection with Herpes Simplex Virus (HSV). Hence the increasing STD worldwide will create the opportunity for the STD testing market.
Market Segmentation: By type the global STD testing market is segmented into fingertip chlamydia testing, syphilis testing, gonorrhea testing, herpes simplex virus testing, human papilloma virus testing, human immunodeficiency virus testing, chancroid testing and others. On the basis of location of testing the global STD testing market is segmented into laboratory testing, Point Of Care (POC) testing and others. Laboratory testing is sub segmented into commercial/private labs and public health labs. On the basis of testing device the global STD testing market is segmented into laboratory devices, Point Of Care (POC) devices and others. Laboratory devices is sub segmented into thermal cyclers – PCR, lateral flow readers – immunochromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate reader – Enzyme Linked Immunosorbent Assay (ELISA) and others. Point Of Care (POC) devices is sub segmented into phone chips (microfluidics + ICT) and portable/bench top/rapid diagnostic kits. Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others. Key Developments in the Market:
Competitive Analysis: The global STD testing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of STD testing market for global, Europe, North America, Asia Pacific and South America. Reasons to Purchase this Report
Customization of the Report
Inquire Regarding This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-std-testing-market Key Questions Answered in Global STD Testing Market Report:- Our Report offers:- What will the market growth rate, Overview and Analysis by Type of Global STD Testing Market 2024? What are the key factors driving, Analysis by Applications and Global STD Testing Market? What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Vendors Profiles of Global STD Testing Market? What are Opportunities, Risk and Driving Force of Global STD Testing Market? What are the opportunities and threats faced by the vendors Global STD Testing Market? What are the Global STD Testing Market opportunities, market risk and market overview of the Market? About Data Bridge Market Research: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: sopan.gedam@databridgemarketresearch.com  |
| Congress faces decision on coronavirus package - Politico Posted: 23 Mar 2020 07:00 AM PDT With Alice Miranda Ollstein Editor's Note: POLITICO Pulse is a free version of POLITICO Pro Health Care's morning newsletter, which is delivered to our subscribers each morning at 6 a.m. The POLITICO Pro platform combines the news you need with tools you can use to take action on the day's biggest stories. Act on the news with POLITICO Pro. — A massive coronavirus stimulus bill is stalled in Congress, as lawmakers are bitterly divided on the historic package's provisions. — Administration and public health officials are grappling with supply shortages and chaotic decision-making that could force hard choices amid the worsening pandemic. — It's the 10th anniversary of Obamacare, and POLITICO looks back on the law's impact. WELCOME BACK TO MONDAY PULSE — Although what even is the "weekend" anymore, really? Tips to [email protected] and [email protected]. DECISION DAY FOR CONGRESS — An effort to take up the $1.6 trillion rescue package failed Sunday night after Senate Democrats denied Republicans the 60 votes needed to move forward. — The GOP and White House insist that a deal must be reached by Monday or financial markets will further deteriorate, exacerbating an already precarious position for the U.S. economy. Senate Majority Leader Mitch McConnell vowed to hold another procedural vote at 9:45 a.m. Monday — "15 minutes after the markets open" — in the absence of an agreement, but was stymied by Democratic objections, forcing the chamber to delay votes to the afternoon. But House Speaker Nancy Pelosi, who McConnell blamed for scuttling the deal, made clear that the Monday timeframe to pass something is McConnell's self-imposed deadline, not hers. — The sticking points in the Senate include provisions for corporations getting federal assistance, including policy on stock buybacks and executive pay, as well as unemployment insurance and worker protections, POLITICO's Marianne LeVine and John Bresnahan report. — Meanwhile, the House is forging ahead with its own package, although it's unclear what will be in the final legislation, POLITICO's Heather Caygle, Sarah Ferris and Marianne report. The caucus held several hours of conference calls this week for members to promote their ideas, including a significant expansion of unemployment insurance, direct cash payments to Americans under a certain income threshold, funding for hospitals and medical supplies, and grants to keep small businesses from folding. Hundreds of proposals were submitted from all corners of the caucus. WHAT HEALTH CARE ADVOCATES WANT TO SEE — They're calling for more direct assistance to hospitals, which have warned that they're facing dire financial straits as demands ramp up. The latest Senate bill offers $75B for providers, far less than the $225B that the Federation of American Hospitals wanted to see. Labs also are warning that the package falls short. "Without sustainable funding, there is simply no way to have sustainable testing," said Julie Khani of the American Clinical Laboratory Association. One group, United States of Care, is even demanding more support for the personnel responding to the crisis. "Our front line health care workers and responders will be the heroes in this fight and they need to be supported the same way we support our military heroes," said Andy Slavitt, the former acting CMS chief who now leads US of Care and is touting a five-point plan for Congress. "We need to announce a $5,000 per month payment to our health care workforce and call up the reserves." MEANWHILE: IS RAND PAUL's DIAGNOSIS A WAKE-UP FOR THE CHAMBER? — The senator's coronavirus diagnosis, coming days after he first took a test and hours after he worked out in the Senate gym, sparked recriminations from colleagues like Sen. Kyrsten Sinema. "This, America, is absolutely irresponsible," Sinema tweeted. "You cannot be near other people while waiting for coronavirus test results. It endangers others & likely increases the spread of the virus." — The ramifications are significant. Sens. Mike Lee and Mitt Romney immediately announced that they would self-quarantine, depriving the Senate GOP of two more reliable votes after Sens. Cory Gardner and Rick Scott already entered self-quarantine. — DIAZ-BALART, McADAMS detail difficult symptoms. The first two members to be diagnosed with coronavirus have opened up about their experiences. "I'm feeling about as sick as I've been," Rep. Ben McAdams said during a CNN interview on Friday. "I got really labored breathing. I feel like I have a belt around my chest, really tight." The Utah Democrat was subsequently hospitalized. Rep. Mario Diaz-Balart said the symptoms "hit him like a ton of bricks." INSIDE THE WHITE HOUSE: 'IT's ALL SHORT-TERM THINKING' — The president's new urgency on coronavirus is better than the weeks of delays, officials say, but it's also created a frantic environment that's swamped long-term planning efforts, POLITICO's Dan Diamond reports. Trump's drive to announce unfinished initiatives also has created a "need to make good on half-baked promises," said one senior official — who, like other Americans, learned about some initiatives only when the president announced them at the White House podium. In recent days, Trump has made misleading claims about a Google effort to expedite drive-through testing; promised a major FDA announcement that failed to materialize; and committed manufacturers like General Motors to produce medical supplies even though the companies' own pledges are much more vague. — One big issue: We're running behind on a national supply strategy. While supply-planning efforts are now underway, some officials warn that the infamous shortage of coronavirus tests is set to be replicated with other shortages across the health system. "Hospitals are going to run out of basic commodities," said one official. — Local leaders said they feel abandoned, with officials saying Sunday they have not received meaningful amounts of federal aid, including the shipments of desperately needed masks and other emergency equipment that administration officials say they have already dispatched, POLITICO's Alice Miranda Ollstein reports HARD CHOICES ARE LOOMING — Medical leaders in coronavirus-stricken Washington state are quietly preparing a bleak triage strategy to determine which patients may have to be denied complete medical care if the system is overwhelmed, the NYT's Karen Weise and Mike Baker report. The federal government also is preparing guidance on how hospitals should function if they run out of supplies and equipment, the Washington Post reports. NATIVE AMERICAN GROUPS BRACE FOR IMPACT — American Indian organizations are warning they're ill-equipped to combat a coronavirus outbreak that's begun to spread quickly within at least one tribe, POLITICO's Adam Cancryn reports. Indian Health Service facilities serving more than 2.5 million American Indians have just 33 ICU beds and 81 ventilators. Some frontline clinics have fewer than a dozen coronavirus tests. And until Saturday, the administration had held up emergency funding for two weeks with little clear explanation. — HHS announced it will send $80 million to tribes and tribal organizations after POLITICO wrote about the delay — a sum twice the amount Congress initially mandated. But tribal leaders say it's still too little, and the Wall Street Journal reported the initial payouts will exclude some of the nation's poorest tribes. IT's OBAMACARE's 10TH ANNIVERSARY — And Trump is still in favor of trying to strike the law in court, even as unemployment surges and Americans' need for health care grows, he appeared to tell WSJ's Andrew Restuccia at a Sunday press conference. — JOE BIDEN is urging Trump to drop the lawsuit. "You have in your power the ability to make life safer, healthier, and a little bit easier for your constituents," the former vice president writes in a letter this morning. "All you have to do is drop your support for this ill-conceived lawsuit, which is even more dangerous and cruel in this moment of national crisis." — JOANNE KENEN on where the ACA could be going next: Gradual improvements. "Democrats tore themselves asunder this primary season over whether to abandon Obamacare for 'Medicare for All,'" Joanne writes. "Yet if history is any lesson, the health care law marking its 10th anniversary on Monday will evolve and, in time, grow more generous." — Oklahoma remains the frontline of one key ACA fight. After years of battles, Oklahomans are finally set to expand Medicaid, POLITICO's Rachel Roubein reports. But Republican Gov. Kevin Stitt is pushing an alternate approach: seeking to remake the state's Medicaid program with Trump's block grant instead. — Meanwhile: the predictions that didn't quite pan out. POLITICO's Dan Goldberg ran through 10 prognostications that missed the mark, from claims that 25 million people would sign up for Obamacare plans to long wait lines that never materialized. CAN PHARMA SAVE THE DAY? — Some Trump administration officials and outsiders are counting on biotech to ride to the rescue. "America is home to a vast, dynamic life-science industry. This is its moment," former FDA Commissioner Scott Gottlieb, who sits on the board of Pfizer and other companies, argues in a WSJ op-ed. "This is why decades of drug investment and development matter so much." … PULSE asked John Arnold, the billionaire critic of the pharma industry, if this crisis is causing him to rethink the industry. "No. I want a vibrant pharma industry. But the system we have incentivizes the wrong things (marginal drugs of protected classes) and exploiting old tech while under-incentivizing what we need, like vaccines & antibiotics," Arnold wrote in reply. "If we pay for value we can get more health at lower cost." ONE LESSON FROM ITALY: TREAT MORE PATIENTS AT HOME — Italian doctors are warning that hospitals themselves have become major vectors for infection, Sharon Begley reports for Stat. "In a pandemic, patient-centered care is inadequate and must be replaced by community-centered care," Italian physicians write in a paper in NEJM Catalyst, adding that they are "learning that hospitals might be the main Covid-19 carriers, as they are rapidly populated by infected patients, facilitating transmission to uninfected patients." STD ERADICATION EFFORTS STALL AMID CORONAVIRUS PANDEMIC — The National Coalition of STD Directors says the vast majority of the nation's Disease Investigation Specialists, or DIS, have been redeployed to trace the spread of coronavirus instead of their regular work tracking HIV and STDs, POLITICO's Alice Miranda Ollstein reports. Additionally, most of the country's STD clinics have either closed or shifted to focus on coronavirus. With STDs already at record rates and coronavirus cases mounting, public health leaders say more funding is needed to adequately address both crises. "Amidst the COVID-19 pandemic and the worst STD epidemic in our history, our public health system is starved for support," said David Harvey, the executive director of the coalition. While the Senate GOP bill that failed to advance Sunday night did include an increase in overall CDC funding that could be used for this purpose, the group argues a specific allocation is needed. They're asking Congress for $200 million to hire more investigation specialists and maintain minimum STD testing and treatment. LOOKING CLOSER AT A CDC STAFFING MOVE — Reuters had an explosive story about the Trump administration eliminating a CDC position in China just months before the coronavirus outbreak, suggesting that the staffer could've alerted U.S. officials about the potential pandemic. "The negligence here is staggering," tweeted Rep. Tim Ryan. But PULSE talked to experts who expressed bipartisan concern that the story's impact was overblown, with several officials cautioning that the CDC position — a mentor to China epidemiologists — wasn't linked to U.S. detection and preparation efforts. "The role of that position is NOT to feed information back to the US, but to support China in doing better epidemiology," Tom Frieden, the former CDC director, told PULSE. The job "may have been helpful" in China's fight against the outbreak, Frieden added. "More than a slim chance, far less than a certainty." Sign up for POLITICO Nightly: Coronavirus Special Edition, your daily update on how the illness is affecting politics, markets, public health and more. He's back: Atul Gawande writes in the New Yorker on how to keep the coronavirus from infecting health workers. "I'm going to keep pushing": Tony Fauci's blunt interview with Science magazine on what it's like inside the White House response. COVID-19 has a weakness: social distancing, as painful as the process can be, NYT's Donald G. McNeil Jr. writes.   |
| You are subscribed to email updates from "free std testing" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment